33
Views
0
CrossRef citations to date
0
Altmetric
Letter to the Editor

Letter to the Editor: “Docetaxel and Its Nanoformulations: How Delivery Strategies Could Impact the Therapeutic Outcome?”

, &
Pages 343-344 | Received 03 Oct 2020, Accepted 16 Mar 2021, Published online: 29 Mar 2021

References

  • Sharma S , PukaleSS , MittalAet al. Docetaxel and its nanoformulations: how delivery strategies could impact the therapeutic outcome? Ther. Deliv. 11(12), 755–759 (2020).
  • World Intellectual Property Organization . Aqueous systems for the preparation of lipid-based pharmaceutical compounds; compositions, methods, and uses thereof. Publication no. WO/2008/127358. (2008). https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2008127358&redirectedID=true
  • Ahmad A , SheikhS , AliSMet al. Development of aqueous based formulation of docetaxel: safety and pharmacokinetics in patients with advanced solid tumors. J. Nanomed. Nanotechnol.6(3), 1 (2015).
  • Greish K . Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Methods Mol. Biol.624, 25–37 (2010).
  • McKeage K . Nanosomal docetaxel lipid suspension: a guide to its use in cancer. Clin. Drug Investig.37(4), 405–410 (2017).
  • Ahmad A , SheikhS , TaranRet al. Therapeutic efficacy of a novel nanosomal docetaxel lipid suspension compared with taxotere in locally advanced or metastatic breast cancer patients. Clin. Breast Cancer14(3), 177–181 (2014).
  • Ashraf M , SajjadR , KhanMet al. 156P Efficacy and safety of a novel nanosomal docetaxel lipid suspension (NDLS) as an anti cancer agent – a retrospective study. Ann. Oncol.27(Suppl. 9), ix46–ix51 (2016).
  • Naik R , KhanMA. DoceAqualip in a patient with prostate cancer who had an allergic reaction to conventional docetaxel: a case report. Mol. Clin. Oncol.6(3), 341–343 (2017).
  • Prasanna R , BungerD , KhanMA. Efficacy and safety of DoceAqualip in a patient with locally advanced cervical cancer: a case report. Mol. Clin. Oncol.8(2), 296–299 (2018).
  • Vyas V , JoshiN , KhanM. Novel docetaxel formulation (NDLS) in low cardiac reserve ovarian cancer. Open Access J. Cancer Oncol.2(2), 000122 (2018).
  • Gupta S , PawarSS , BungerD. Successful downstaging of locally recurrent penile squamous cell carcinoma with neoadjuvant nanosomal docetaxel lipid suspension (NDLS) based regimen followed by curative surgery. BMJ Case Rep.2017, (2017). https://doi.org/10.1136/bcr-2017-220686
  • Murali A , GuptaS , PendharkarD. Efficacy and tolerability of nanoparticle docetaxel lipid suspension. J. Clin. Oncol.36(Suppl. 15), e14542–e14542 (2018).
  • Narayanan P , DattatreyaPS , PrasannaRet al. Efficacy and safety of nanosomal docetaxel lipid suspension-based chemotherapy in sarcoma: a multicenter, retrospective Study. Sarcoma2019, 3158590–3158590 (2019).
  • Rajappa S , JoshiA , DovalDCet al. Novel formulations of docetaxel, paclitaxel and doxorubicin in the management of metastatic breast cancer. Oncol. Lett.16(3), 3757–3769 (2018).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.